Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Acquisitions Lift Perrigo 5%

By Drug Discovery Trends Editor | November 1, 2013

(Source: Perrigo)Drugmaker Perrigo said its net income rose 5 percent in the fiscal first quarter as a series of acquisitions boosted its sales.
 
Since late 2012 Perrigo Co. has bought Sergeant’s Pet Care Products, Rosemont Pharmaceuticals and Velcera Inc., which makes the flea and tick treatment PetArmor. Sales were also aided by new products for coughs and colds and smoking-cessation products. The company’s fiscal first quarter ended on Sept. 28.
 
In July it agreed to buy Irish drugmaker Elan Corp. PLC in its largest acquisition. Perrigo expects the $8.6 billion deal to close by the end of December.
 
Perrigo said its net income grew to $111.4 million, or $1.18 per share, from $105.6 million, or $1.12 per share. Excluding one-time charges the company said it earned $1.52 per share. Revenue grew 21 percent to $933.4 million.
 
Analysts expected net income of $1.39 per share and $896.4 million in revenue, according to FactSet.
 
Perrigo still expects to earn between $6.35 and $6.60 per share in the current fiscal year. Analysts are forecasting adjusted net income of $6.56 per share.
 
Date: October 31, 2013
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50